| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
Angiotensin (1-12) targets the angiotensin II receptor as a precursor. It is an activator of the receptor and can be used to identify antibodies against the protein. The peptide has been shown to inhibit ion channels and bind with high affinity to the angiotensin II receptor. Its role as a precursor for local angiotensin production makes it a valuable tool for studying the renin-angiotensin system.
|
|---|---|
| ln Vitro |
In vitro, Angiotensin (1-12) is used as a research tool to study angiotensin II and its receptor. It binds with high affinity to the angiotensin II receptor. The peptide inhibits ion channels and can be used to identify antibodies against the angiotensin II receptor protein. Its activity is modulated by captopril and CV-11974, which eliminate its vasoconstrictor and pressor responses.
|
| ln Vivo |
In vivo, Angiotensin (1-12) produces vasoconstrictor and pressor responses upon intravenous infusion. These responses are eliminated by captopril and CV-11974, an angiotensin II type 1 receptor antagonist. The peptide is expressed in a wide range of organs including the heart, kidneys, liver, spleen, and small intestine. It represents a potential precursor for local angiotensin production in these tissues.
|
| Enzyme Assay |
For non-cellular assays, Angiotensin (1-12) is evaluated for its binding affinity to the angiotensin II receptor using radioligand binding assays. Receptor binding is assessed using purified receptor preparations or membrane fractions. The peptide's ability to inhibit ion channels is evaluated using patch-clamp techniques or ion flux assays in cell-free systems. Binding affinity and potency are determined from dose-response curves.
|
| Cell Assay |
In vitro cell culture experiments are performed using cells expressing angiotensin II receptors. Cells are treated with Angiotensin (1-12) at various concentrations. Endpoints include receptor activation (calcium flux, cAMP modulation), downstream signaling (MAPK activation), and cellular responses (contraction, proliferation). The peptide's activity is compared to angiotensin II and other angiotensin peptides. Inhibitors such as captopril and CV-11974 are used to confirm receptor specificity.
|
| Animal Protocol |
In vivo animal studies are conducted in mouse and rat models. Angiotensin (1-12) is administered intravenously. Hemodynamic parameters including blood pressure and vascular resistance are measured. Vasoconstrictor and pressor responses are assessed. The effects of captopril and CV-11974 on these responses are evaluated to confirm the peptide's role in the renin-angiotensin system. Tissue expression of the peptide is confirmed by immunohistochemistry or Western blot.
|
| ADME/Pharmacokinetics |
Angiotensin (1-12) has a molecular formula of C77H109N19O17 and a molecular weight of 1572.83 g/mol. It is a peptide with the sequence H2N-DRVYIHPFHLLY-OH. The peptide is typically stored as a lyophilized powder and reconstituted in appropriate buffers for experimental use. Pharmacokinetic properties are characteristic of peptides, with rapid clearance and limited oral bioavailability. It is stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Toxicological profiles of Angiotensin (1-12) are not well characterized. As a naturally occurring peptide, it is expected to have low toxicity at physiological concentrations. Standard laboratory safety precautions should be followed during handling. The compound is for research use only and is not intended for therapeutic applications.
|
| Additional Infomation |
Angiotensin (1-12) (mouse, rat) is a peptide that serves as a potential precursor for local angiotensin production. It is expressed in multiple organs including the heart, kidneys, liver, spleen, and small intestine. The peptide binds with high affinity to the angiotensin II receptor and its vasoconstrictor responses are blocked by captopril and CV-11974. It is used as a research tool for studying the renin-angiotensin system.
|
| Molecular Formula |
C77H109N19O17
|
|---|---|
| Exact Mass |
1571.82
|
| CAS # |
914910-73-9
|
| PubChem CID |
131863372
|
| Sequence |
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Tyr
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.41±0.1 g/cm3(20 °C , 760mmHg)
|
| LogP |
5.578
|
| Hydrogen Bond Donor Count |
20
|
| Hydrogen Bond Acceptor Count |
21
|
| Rotatable Bond Count |
46
|
| Heavy Atom Count |
113
|
| Complexity |
3170
|
| Defined Atom Stereocenter Count |
13
|
| SMILES |
C(N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)O)CC1C=CC(O)=CC=1)CC1NC=NC=1)CC1C=CC=CC=1)(=O)[C@@H](NC(=O)[C@]([H])([C@@H](C)CC)NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(=O)O)CC1C=CC(O)=CC=1)CC1NC=NC=1
|
| InChi Key |
MAORFXTUYRZLDZ-XGGOVCPUSA-N
|
| InChi Code |
InChI=1S/C77H109N19O17/c1-9-44(8)64(95-71(107)57(32-46-19-23-50(97)24-20-46)91-73(109)63(43(6)7)94-66(102)53(17-13-27-83-77(79)80)86-65(101)52(78)36-62(99)100)74(110)92-59(35-49-38-82-40-85-49)75(111)96-28-14-18-61(96)72(108)90-56(31-45-15-11-10-12-16-45)69(105)89-58(34-48-37-81-39-84-48)70(106)88-54(29-41(2)3)67(103)87-55(30-42(4)5)68(104)93-60(76(112)113)33-47-21-25-51(98)26-22-47/h10-12,15-16,19-26,37-44,52-61,63-64,97-98H,9,13-14,17-18,27-36,78H2,1-8H3,(H,81,84)(H,82,85)(H,86,101)(H,87,103)(H,88,106)(H,89,105)(H,90,108)(H,91,109)(H,92,110)(H,93,104)(H,94,102)(H,95,107)(H,99,100)(H,112,113)(H4,79,80,83)/t44-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,63-,64-/m0/s1
|
| Chemical Name |
(3S)-3-amino-4-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
